Full Breakdown
Investigation into Alleged Fraudulent Billing Practices in Gender-Affirming Care
10/11/2025, 3:37:22 PM
Overview of the Investigation
The U.S. Department of Justice (DOJ) is conducting a nationwide investigation into potential fraudulent billing practices related to gender-affirming medical care for minors, specifically targeting the Children’s Hospital of Philadelphia (CHOP) and UPMC Children’s Hospital of Pittsburgh. The inquiry, initiated under the Trump administration, focuses on whether these hospitals misrepresented diagnoses to secure insurance coverage for off-label prescriptions of puberty blockers and hormones used in treating gender dysphoria.
Allegations Against CHOP and UPMC
In recent court filings, the DOJ has claimed to possess evidence suggesting that CHOP and UPMC may have engaged in fraudulent billing practices. The DOJ's acting director of the Enforcement and Affirmative Litigation Branch, Lisa Hsiao, stated that there is reason to suspect that doctors at CHOP have been using incorrect diagnoses, such as "central precocious puberty," to obtain insurance coverage for treatments that may not be reimbursable under federal law. Hsiao noted that between 2017 and 2024, CHOP diagnosed approximately 250 minors over the age of 10 with this condition, which is atypical for the diagnosis.
Legal Context and Responses
The investigation has led to subpoenas issued to CHOP and UPMC, seeking detailed patient records, billing codes, and internal communications. CHOP has filed a motion to limit the DOJ's subpoena power, arguing that the new allegations presented by the DOJ were improperly submitted and lack credibility. The hospital's legal team highlighted that Hsiao's earlier declaration referred to a lawsuit that was later removed without explanation, raising concerns about the integrity of the DOJ's claims.
UPMC has also faced scrutiny but has stated that there are no specific allegations of fraud against its facility. In June, UPMC announced it would cease providing gender-affirming care for patients under 19, citing legal risks associated with the ongoing investigation.
Criticism and Opposition
Critics of the DOJ's investigation argue that it represents a politically motivated effort to undermine access to gender-affirming care for minors. Legal representatives for affected patients contend that the subpoenas infringe upon privacy rights and that the government is attempting to criminalize legal medical practices. Mimi McKenzie, legal director at the Public Interest Law Center, stated that the DOJ's actions reflect an agenda to end gender-affirming care rather than a genuine concern for patient safety.
Broader Implications
The investigation has sparked a national debate regarding the legality and ethics of gender-affirming medical care for minors. Advocates for transgender youth warn that the DOJ's actions could deter healthcare providers from offering necessary treatments, thereby jeopardizing the mental health and well-being of vulnerable populations. The outcome of this investigation may have significant implications for the future of gender-affirming care across the United States.
Verbatim Quotes
- “This is a bona fide, high-priority and substantial national investigation of potential (federal Food, Drug and Cosmetic Act) violations in the provision of gender-related care for minors.” — Lisa Hsiao, Acting Director, DOJ Enforcement and Affirmative Litigation Branch
- “At the heart of this, the administration wants to end gender-affirming care. You can’t weaponize the DOJ to advance your political agenda.” — Mimi McKenzie, Legal Director, Public Interest Law Center
- “Medical professionals and organizations that mutilated children in the service of a warped ideology will be held accountable by this Department of Justice,” — Pam Bondi, Attorney General
Conflicting Reports & Gaps
While the DOJ claims to have evidence of fraudulent practices, specific allegations against UPMC remain unsubstantiated. Additionally, the removal of references to a lawsuit in Hsiao's declaration raises questions about the reliability of the DOJ's assertions. The investigation continues to unfold, with ongoing legal challenges from the hospitals involved.
